Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Public Citizen: Victory for Investors - SEC Won't Stop Johnson, Johnson From Rejecting Shareholder Arbitration Proposal That Might Be Illegal

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/12/2019 | 09:32am EDT

WASHINGTON, Feb. 11 -- Public Citizen issued the following statement by Lisa Gilbert, vice president of legislative affairs:

Today, the U.S. Securities and Exchange Commission (SEC) issued the "no action" letter to Johnson & Johnson that Public Citizen called for (PDF) in December. The letter states that the SEC will take no action against Johnson & Johnson if the company excludes from its proxy materials a shareholder proposal that would force investor disputes into mandatory arbitration. The SEC's staff made this determination after the New Jersey attorney general asserted that the arbitration proposal would violate state law.

"The U.S. Securities and Exchange Commission (SEC) did the right thing by deciding not to take action against Johnson & Johnson and protecting investors against forced arbitration.

"While this is a significant victory, investors need real and lasting protections, which is why Congress must immediately ban forced arbitration.

"This issue will not go away because corporate interests will continue to hound the SEC to restrict the rights of investors. We must ensure that the SEC continues to allow investors to hold corporate wrongdoers accountable."

© 2019 Targeted News Service, source News Service

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
05:11aJOHNSON & JOHNSON : TB Alliance and Mylan Announce Global Collaboration to Comme..
AQ
02:35aFDA orders companies to stop sale of pelvic surgical mesh in US
AQ
04/18Pfizer, Johnson & Johnson Weigh on Pharmaceutical ETFs
DJ
04/17GENMAB : Announces Net Sales of DARZALEX for First Quarter of 2019
AQ
04/17JOHNSON & JOHNSON : Balversa receives U.S. FDA approval for the treatment of pat..
AQ
04/17JOHNSON & JOHNSON : Higher Drug Sales Aid J&J Results
DJ
04/17JOHNSON & JOHNSON : Wall St edges up on positive earnings data
AQ
04/16JOHNSON & JOHNSON : Qualcomm and Progressive jump while Wave Life Sciences drops
AQ
04/16MARKET SNAPSHOT: Stocks Close Higher As Nasdaq Reclaims The 8,000-mark After ..
DJ
04/16JOHNSON & JOHNSON : Pharmaceuticals drive J&J to better-than-expected quarterly ..
RE
More news
Financials ($)
Sales 2019 81 168 M
EBIT 2019 25 628 M
Net income 2019 19 012 M
Debt 2019 1 998 M
Yield 2019 2,74%
P/E ratio 2019 19,63
P/E ratio 2020 17,33
EV / Sales 2019 4,54x
EV / Sales 2020 4,22x
Capitalization 366 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 147 $
Spread / Average Target 7,1%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Charles O. Prince Independent Director
William David Perez Independent Director
Anne M. Mulcahy Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON6.56%366 184
ROCHE HOLDING LTD.8.22%224 445
PFIZER-9.78%218 630
NOVARTIS3.69%194 472
MERCK AND COMPANY-4.21%189 055
ELI LILLY AND COMPANY-0.45%119 326